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CASE REPORT
Nonalcoholic fatty liver disease (NAFLD) repre-
sents a broad disease spectrum, ranging from
simple steatosis without inflammation, to non-
alcoholic steatohepatitis (NASH) with inflam-
mation, fibrosis and even cirrhosis in patients
who deny alcohol abuse.1 Risk factors for the de-
velopment of NAFLD include major components
of the metabolic syndrome: obesity, type 2 dia-
betes, and dyslipidemia.2–5 NAFLD has been in-
creasingly recognized as the most common liver
disease in Western countries where the preva-
lence is estimated to be about 20–30%, while
NASH affects about 2–3% of the general popula-
tion.6,7 With the westernization of lifestyle and
diet patterns in recent decades, the prevalence of
obesity and overweight has been increasing in
many Asian countries including Taiwan. However,
the emergence of NAFLD and its clinical impact
seems to have been overlooked in this region.
Herein, we report a Taiwanese patient who had
abnormal liver tests for 18 years, and paired liver
biopsies performed 17 years apart confirmed the
diagnosis and histologic progression of NASH.
Case Report
A 43-year-old man was incidentally found to
have elevated serum alanine aminotransferase
(ALT) and aspartate aminotransferase (AST) levels
in February 1987. He was referred to our hospi-
tal for further evaluation. He denied the history
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of alcohol abuse, any drugs or toxin exposure,
and blood transfusion. None of his family had
history of chronic liver disease. At that time, his
body weight was 77 kg and body height was
173.5 cm (body mass index [BMI], 25.6 kg/m2).
Serum ALT level was 59 IU/L (upper limit of nor-
mal [ULN], < 37 IU/L) and serum AST level was
40 IU/L (ULN, < 37 IU/L). Blood pressure, blood
sugar, serum albumin, globulin, bilirubin, alka-
line phosphatase and γ-glutamyl transferase levels
were all within normal limits. Serum total cho-
lesterol (T-CHO) level was 233 mg/dL (ULN,
< 220 mg/dL) and triglyceride (TG) level was
68 mg/dL (ULN, < 150 mg/dL). Hepatitis viral
markers in February 1987 revealed that he was
negative for both hepatitis B surface antigen
(HBsAg) and antibody against HBsAg (anti-HBs),
and positive for antibody against hepatitis B core
antigen (anti-HBc). Antibody against hepatitis C
virus (anti-HCV), performed in February 2000
when the assay was available, was also negative.
Serological studies excluded the presence of au-
toimmune hepatitis and inherited/metabolic liver
diseases. Abdominal ultrasonography showed a
small hemangioma at the right lobe of the liver.
His hepatic parenchyma was fine in echotexture
and there was no evidence of fatty liver. Since
viral hepatitis, drug-induced liver injury and 
autoimmune liver disease had been ruled out,
the diagnosis of cryptogenic hepatitis was made.
Liver biopsy was performed after 18 months of
persistently elevated serum ALT and AST. Histo-
logic examination disclosed evidence of steato-
hepatitis: diffuse micro- and macrovesicular fatty
changes in the hepatocytes; mild focal necrosis
of the hepatocytes in the lobules, accompanied
by mild mononuclear cell infiltration in portal
and lobular areas; and mild focal perivenous fi-
brosis (Figure 1). Based on Brunt’s criteria, the
necroinflammatory activity was grade 1 and the
fibrosis was stage 1.8
Over the next 12 years, serum AST and ALT
levels increased gradually to 6–8 × ULN. Hepatitis
B and C viral serologic markers were repeatedly
negative. Serum HBV DNA and HCV RNA were
also undetectable by polymerase chain reaction
assays when the techniques became available.
Alcohol abuse and drugs or toxin exposure were
denied. Evidence of autoimmune liver disease
was not found during follow-up. Meanwhile, his
body weight increased to 83 kg (BMI, 27.6 kg/m2)
in 1999. Moreover, serum lipid profile revealed
that T-CHO level was 344 mg/dL, TG level was
152 mg/dL, low-density lipoprotein (LDL) level
was 273 mg/dL, and high-density lipoprotein
(HDL) level was 40 mg/dL. Fasting serum glu-
cose level was 83 mg/dL. Simvastatin was thus
prescribed and his serum T-CHO decreased to
133 mg/dL in May 2001. Serum AST and ALT 
levels improved in parallel (AST, 46 IU/L; ALT,
A B
Figure 1. First liver biopsy (August 1988) reveals diffuse micro- and macrovesicular fatty changes in the hepatocytes. 
(A) Mild mononuclear cell infiltrations in portal and lobular areas (black arrow; hematoxylin & eosin, 400×). (B) Focal
mild perivenous fibrosis (white arrow; hematoxylin & eosin, 400×). The necroinflammatory activity is graded 1 and the 
fibrosis is staged 1 by Brunt et al’s criteria.8
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89 IU/L). However, drug compliance was not sat-
isfactory and his body weight increased gradu-
ally to 86.6 kg (BMI, 28.8 kg/m2) in December
2004, 17 years after his first visit to our hospital,
accompanied by deterioration in serum AST and
ALT levels. The chronological data of serum AST,
ALT, TG and T-CHO levels, and BMI during 
follow-up are shown in Figure 2.
Abdominal ultrasonography performed in May
2005 showed the presence of fatty liver of mod-
erate degree in addition to a small hemangioma.
In June 2005, his body height was 173.5 cm and
body weight was 86.0 kg (BMI, 28.6 kg/m2). His
waist circumference was 91 cm. The body tempera-
ture was 36.6°C, pulse rate was 72 per minute, res-
piratory rate was 20 per minute, and blood pressure
was 106/70 mmHg. Other physical findings were
unremarkable. The white blood cell count was
5850/mm3. Blood sugar level was 95 mg/dL before
meal and 128 mg/dL 2 hours after meal. Serum
AST and ALT levels were 56 IU/L and 119 IU/L,
respectively. Serum lipid profile revealed that T-
CHO level was 306 mg/dL, TG level was 102 mg/
dL, LDL level was 242 mg/dL, and HDL level was
44 mg/dL. He received follow-up needle biopsy
of the liver on July 14, 2005, 17 years after the
first biopsy. Histologic features again disclosed
evidence of steatohepatitis: diffuse micro- and
macrovesicular fatty changes of the hepatocytes;
lymphocytic and occasional neutrophilic infiltra-
tion in portal and lobular areas; and fibrosis at the
portal, perivenular and pericentral venous areas
with septum formation, which was confirmed by
Masson-Trichrome stain (Figure 3). The histology
was therefore designated grade 1 necroinflamma-
tion and stage 2 fibrosis based on the same criteria
of Brunt et al.8
Discussion
We report a histologically proven case of NASH
in a Taiwanese patient, who had metabolic de-
rangements and a long-term follow-up for more
than 18 years. This patient documented the exis-
tence of NAFLD/NASH in Taiwan with possible
histologic progression.
The development of NAFLD/NASH has been
linked to insulin resistance and it is now consid-
ered a hepatic manifestation of the metabolic
syndrome.3,9,10 However, the criteria for the diag-
nosis of metabolic syndrome are set according to
studies in Western countries and may not be suit-
able for Asian populations.11 For example, recent
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Figure 2. Chronological profile of body mass index (BMI), serum aspartate aminotransferase (AST) level, serum alanine
aminotransferase (ALT) level, serum total cholesterol (T-CHO) level, and serum triglyceride (TG) level during an 18-year
follow-up.
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studies suggested that the risk of obesity in Asians
may be higher than that of other ethnic groups
using the same BMI cutoff values. Accordingly,
the definition of overweight and obesity in
Taiwanese may be better set as BMI > 24 kg/m2
and > 27 kg/m2, respectively. In the present case,
if we used the modified criteria, he would already
be overweight at the initial visit (BMI, 25.6 kg/m2)
and obese at the last visit (BMI, 28.6 kg/m2). The
presence of metabolic derangement most likely
accounted for the development of NAFLD/NASH
in this patient.
The diagnosis of NAFLD and NASH relies on
clinical suspicion and histopathologic findings.
Mildly to moderately elevated serum aminotrans-
ferase levels are common. Imaging studies may
provide evidence of fatty infiltration of the liver
but cannot differentiate simple steatosis from
NASH.12 Therefore, liver biopsy remains the def-
inite diagnostic procedure.3 In the present case,
initial abdominal ultrasonography did not show
the typical features of liver brightness, blurring of
vessel walls nor fat attenuation.13 However, the
presence of diffuse steatosis was found by liver
biopsy, which consistently supported the role 
of liver biopsy for accurate diagnosis. The pattern
of steatosis in NASH/NAFLD is mostly macro-
vesicular and secondly mixed macrovesicular
and microvesicular,8 as seen in the present case.
The pattern of true microvesicular steatosis, con-
sisting of much smaller and uniform fat droplets
dispersed throughout the hepatocyte, was not
found in the pathologic examinations of the
case. Furthermore, the possibility of toxin expo-
sure, the most common cause of microvesicular
steatosis, was also excluded by history. As to the
management of NAFLD and NASH, currently,
there is still no proven effective drug therapy. 
A recent study has revealed that aggressive body
weight control was followed by improvement in
the biochemical and histologic profiles of NASH
patients.14 In our patient who had underlying
obesity and hyperlipidemia, weight reduction
was suggested and the lipid-lowering agent sim-
vastatin was used. Interestingly, clinical improve-
ment of both total cholesterol level and liver
function test was documented, although only
transiently due to his poor drug compliance and
progressively increasing body weight.
The natural history of NAFLD correlates with
baseline histologic findings.15 Retrospective co-
hort studies suggested that patients with simple
steatosis usually run a benign course with a neg-
ligible risk of developing cirrhosis over 15–20
years. In contrast, patients with NASH and fibro-
sis can progress to cirrhosis with a risk ranging
from 0% to 12% over 5–8 years’ follow-up.1,16–18
Data on the prevalence and natural course in
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Figure 3. Second liver biopsy (July 2005) reveals diffuse micro- and macrovesicular fatty changes of the hepatocytes, 
accompanied by lymphocytic and occasional neutrophilic infiltrations in the portal and lobular areas. (A) Fibrosis at the
portal area (black arrow; hematoxylin & eosin, 400×). (B) Fibrosis at the portal, perivenular and pericellular areas with
septal formation (white arrow; Masson-trichrome stain, 200×). The necroinflammatory activity is graded 1 and the fibrosis
is staged 2 by Brunt et al’s criteria.8
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Chinese populations are limited in the literature.
Wong et al reviewed the clinical and histologic
features of 42 patients with biopsy-proven NAFLD
in Hong Kong.19 They found that most patients
had features of metabolic syndrome. As high as
85.7% of NAFLD patients had evidence of steato-
hepatitis and 26.1% had fibrosis according to
Brunt’s criteria. They further investigated the his-
tologic progression in 17 Chinese patients with
paired liver biopsy.20 Nine (53%) of them had a
progressive disease with worsening of fibrosis
score during a median histologic follow-up period
of 6.1 years (range, 3.8–8.0 years). In our patient
with a paired histologic follow-up of over 17 years,
we also demonstrated the benign but slowly pro-
gressive course of NASH.
In Taiwan, chronic viral hepatitis including
hepatitis B and C is the most common cause of
liver disease. However, with the control of chronic
viral hepatitis by universal vaccination and effec-
tive antiviral therapies, NAFLD/NASH will become
major liver diseases in the Taiwanese people. The
prevalence of fatty liver was found to be around
40% by ultrasonography in a hospital-based health
check-up series.21 NASH has been reported in
morbidly obese patients in Taiwan with a preva-
lence of 33.8%.22 Nevertheless, the prevalence of
NAFLD and NASH in the general population of
Taiwan remains to be studied. From another as-
pect, whether NAFLD superimposed on patients
with underlying chronic viral hepatitis contributes
to the progression of liver diseases should also be
seriously considered. In our retrospective studies,
hepatic steatosis was found in 46% of patients
with chronic hepatitis C, but steatohepatitis was
uncommonly encountered (4%). Furthermore, the
presence of steatosis might adversely affect the
response to antiviral therapy.23,24 These findings
indicate that correcting metabolic derangement
might help to improve the response to antiviral
therapies.
In summary, we documented a case of NASH
and showed progression of the disease in a
Taiwanese man. NAFLD, a health burden in West-
ern countries, will very likely prevail in Oriental
countries in the near future. Clinicians in Taiwan
should become aware of the issues of NAFLD,
apart from the well-known facts of chronic viral
hepatitis B and C. The role of correcting metabolic
derangement in preventing the progression of
NAFLD and the impact of coexisting NAFLD on
the natural history and antiviral treatment out-
comes in patients with underlying chronic viral
hepatitis merit further studies.
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